Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

A Phase Ib, Open Label, Parallel-Design Single- and Multiple-Dose Study Comparing Modified Release Topiramate Formulations to Immediate Release Formulations of Topiramate Dosed in Combination With Immediate Release Phentermine in Obese Adults

The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.

Study Overview

• Status: Completed
• Conditions: Obesity
• Intervention / Treatment: Drug: topiramate; Drug: phentermine; Drug: topiramate; Drug: phentermine

• Study Type: Interventional
• Enrollment (Actual): 64
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Mountain View, California, United States, 94040
      • Vivus, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years to 61 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Obese adults
• Body mass index between 30.0 and 42.0 kg/m2 (inclusive)
• Medically healthy with no clinically significant results of screening exams

Exclusion Criteria:

• History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
• History of glaucoma or increased intraocular pressure
• History of kidney stones
• Cholelithiasis or cholecystitis within 6 months
• Cardiovascular event within 6 months
• Obesity of known genetic or endocrine origin
• Recent weight instability
• Use of Very Low Calorie diet or participation in organized weight loss program within 3 months
• Systolic blood pressure > 150 or diastolic > 95 mm Hg
• Positive urine drug or alcohol screen
• Positive serology for HIV, HBV, or HCV
• History of alcoholism or drug abuse
• History of significant psychiatric disease, current depression of moderate or greater severity, any history of suicidal ideation
• Hypersensitivity to study drug or related compounds
• Use of prescription or OTC medication other than hormonal contraceptive within 14 days prior to first dosing with study drug
• Blood donation or significant blood loss within 56 days or plasma donation within 7 days prior to first dosing with study drug
• Women who are pregnant or lactating
• Hemoglobin < 12 g/dL
• Use of tobacco or nicotine-containing products within 6 months

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: treatment 1; One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2. One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2.	Drug: topiramate; 25 mg modified-release capsules; Drug: phentermine; 7.5 mg immediate-release capsules; Drug: topiramate; 100 and 25 mg immediate-release tablets; Drug: phentermine; 37.5 and 7.5 mg immediate-release tablets
Experimental: treatment 2; Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2. One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2.	Drug: topiramate; 25 mg modified-release capsules; Drug: phentermine; 7.5 mg immediate-release capsules; Drug: topiramate; 100 and 25 mg immediate-release tablets; Drug: phentermine; 37.5 and 7.5 mg immediate-release tablets
Experimental: treatment 3; Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2. Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2.	Drug: topiramate; 25 mg modified-release capsules; Drug: phentermine; 7.5 mg immediate-release capsules; Drug: topiramate; 100 and 25 mg immediate-release tablets; Drug: phentermine; 37.5 and 7.5 mg immediate-release tablets
Experimental: treatment 4; Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1. One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2. Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2. Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2. Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2.	Drug: topiramate; 25 mg modified-release capsules; Drug: phentermine; 7.5 mg immediate-release capsules; Drug: topiramate; 100 and 25 mg immediate-release tablets; Drug: phentermine; 37.5 and 7.5 mg immediate-release tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Pharmacokinetic parameters	One month

Collaborators and Investigators

• Sponsor: VIVUS LLC
• Investigators: Study Director: Wesley W Day, PhD, VIVUS LLC

Study record dates

Study Major Dates

• Study Start: July 1, 2007
• Primary Completion (Actual): September 1, 2007
• Study Completion (Actual): December 1, 2007

Study Registration Dates

• First Submitted: August 16, 2007
• First Submitted That Met QC Criteria: August 16, 2007
• First Posted (Estimate): August 20, 2007

Study Record Updates

• Last Update Posted (Estimate): June 8, 2011
• Last Update Submitted That Met QC Criteria: June 6, 2011
• Last Verified: June 1, 2011

More Information

Terms related to this study

• Keywords: Obesity
• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Overweight; Body Weight; Obesity; Hypoglycemic Agents; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Anticonvulsants; Appetite Depressants; Anti-Obesity Agents; Central Nervous System Stimulants; Sympathomimetics; Topiramate; Phentermine
• Other Study ID Numbers: OB-102 / AA42851